Fortress BiotechFBIO -8.61%44 Quick Ratio is 2.77 as of Mar. 2026, which is 5% above its 10-year median of 2.63. GuruFocus rates FBIO with a GF Score™ of 44/100 and a GF Value™ of $1.23 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 1,416 Biotechnology companies, Fortress Biotech ranks worse than 57.91% on this metric.
Fortress Biotech has a quick ratio of 2.77. It generally indicates good short-term financial strength.
The historical rank and industry rank for Fortress Biotech's Quick Ratio or its related term are showing as below:
FBIO'
s Quick Ratio Range Over the Past 10 Years
Min: 0.89 Med: 2.63 Max: 6.35
Current: 2.77
During the past 13 years, Fortress Biotech's highest Quick Ratio was 6.35. The lowest was 0.89. And the median was 2.63.
FBIO's Quick Ratio is ranked worse than 57.91% of 1416
companies
in the Biotechnology industry
Industry Median: 3.6
vs FBIO: 2.77
Fortress Biotech (NAS:FBIO) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Fortress Biotech Quick Ratio Related Terms
Fortress Biotech Quick Ratio Historical Data
* Premium members only.
The historical data trend for Fortress Biotech's Quick Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Fortress Biotech's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Fortress Biotech Quick Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Fortress Biotech's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Fortress Biotech's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
Fortress Biotech's Quick Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Fortress Biotech (FBIO) has a Quick Ratio of 2.77 as of Mar. 2026. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Fortress Biotech and its competitors. This is near median its historical median of 2.63. Over the past decade, Fortress Biotech's Quick Ratio has ranged from 0.89 to 6.35. According to the industry distribution chart, Fortress Biotech ranks #820 out of 1416 companies in the Biotechnology industry, placing it in the top 57.9%.
Is Fortress Biotech's Quick Ratio too high?
Fortress Biotech's current Quick Ratio of 2.77 is near median its 10-year median of 2.63. Over the past 10 years, this metric has ranged from a low of 0.89 to a high of 6.35. The Biotechnology industry median Quick Ratio is 3.60. Fortress Biotech's value of 2.77 is 23.1% below this industry median. Based on the distribution chart, Fortress Biotech ranks #820 out of 1416 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Fortress Biotech has a GF Score™ of 44/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Fortress Biotech's Quick Ratio compare to PTHS and IBIO?
According to the Biotechnology industry distribution chart, Fortress Biotech ranks #820 out of 1416 companies for Quick Ratio. This places Fortress Biotech in the lower half of its industry. The industry median Quick Ratio is 3.60. Fortress Biotech's value of 2.77 is 23.1% below this benchmark. Historically, Fortress Biotech's own Quick Ratio has ranged from 0.89 to 6.35 over the past decade. While the company's 10-year median is 2.63 vs. the industry median of 3.60, Fortress Biotech has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Biotechnology company?
The median Quick Ratio among Biotechnology companies is 3.60, based on 1,416 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Fortress Biotech's current Quick Ratio of 2.77 is 23.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Fortress Biotech and its competitors. For the Biotechnology industry, the median Quick Ratio is 3.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Fortress Biotech's current Quick Ratio is 2.77, which is near median its own 10-year median of 2.63. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fortress Biotech stock overvalued right now?
Based on GuruFocus' analysis, Fortress Biotech (FBIO) is currently considered Significantly Overvalued. The stock's GF Value™ is $1.23, compared to a current price of $2.74 — trading 122.8% above its estimated fair value. The current Quick Ratio is 2.77, which is near median its 10-year median of 2.63 and 23.1% below the Biotechnology industry median of 3.60. Fortress Biotech's overall GF Score™ is 44/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For Fortress Biotech (FBIO), the current Quick Ratio is 2.77 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Fortress Biotech (FBIO) Overvalued in 2026?
Based on GuruFocus' analysis, Fortress Biotech stock appears to be overvalued.
The current stock price of $2.74 is trading 122.8% above its estimated GF Value™ of $1.23.
GuruFocus considers Fortress Biotech to be Significantly Overvalued.
Key valuation signals for FBIO:
Quick Ratio: 2.77 (near median its 10-year median of 2.63)
GF Value™: $1.23 vs. price of $2.74 (122.8% above fair value)
Industry Position: 23.1% below the Biotechnology median (#820 of 1416)
No single metric tells the full story. See the FBIO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing, and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, and Exelderm. The business activities of the group are functioned through Dermatology Product Sales, and Pharmaceutical and Biotechnology Product Development.
44GF Score
Get the complete analysis for FBIO
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FBIO has been successfully added to your 
